Sintx Technologies (NASDAQ:SINT) & OPKO Health (NASDAQ:OPK) Head-To-Head Comparison

Sintx Technologies (NASDAQ:SINT) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Risk and Volatility

Sintx Technologies has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.

Institutional and Insider Ownership

18.4% of Sintx Technologies shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 4.1% of Sintx Technologies shares are held by insiders. Comparatively, 49.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Sintx Technologies and OPKO Health”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$2.89 million	3.79	-$11.02 million	($5.66)	-0.53
OPKO Health	$642.07 million	1.36	-$53.22 million	($0.25)	-4.54

Sintx Technologies has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Sintx Technologies and OPKO Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1	0	1	0	2.00
OPKO Health	1	3	2	1	2.43

Sintx Technologies presently has a consensus target price of $16.00, suggesting a potential upside of 438.00%. OPKO Health has a consensus target price of $2.28, suggesting a potential upside of 101.17%. Given Sintx Technologies’ higher possible upside, equities research analysts clearly believe Sintx Technologies is more favorable than OPKO Health.

Profitability

This table compares Sintx Technologies and OPKO Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-775.12%	-218.25%	-95.06%
OPKO Health	-28.10%	-13.67%	-8.70%

Summary

OPKO Health beats Sintx Technologies on 11 of the 15 factors compared between the two stocks.

About Sintx Technologies

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

About OPKO Health

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.